Obesity is an epidemic, complex disease that is characterized by a state of increased glucose, lipids 31 and low-grade inflammation in circulation, among other factors. This is the perfect scenario for the 32 production of ceramide, the building block of the sphingolipid family of lipids, which is involved 33 in metabolic disorders such as obesity, diabetes and cardiovascular disease. In addition, obesity 34 causes a decrease in fatty acid oxidation, which contributes to lipid accumulation within the cells, 35
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Obesity reflects an imbalance between energy intake and energy expenditure and is characterized 57
by excessive fat accumulation in adipose tissue and other organs that has a negative impact on 58 health. It has been established that obesity is a risk factor for other pathological conditions such as 59 insulin resistance and type 2 diabetes mellitus (T2DM) (2), as well as non-alcoholic fatty liver 60 disease (3), cardiovascular disease (5) and cancer (6), among others. During obesity, adipose tissue 61 expands to cope with extra nutrients in circulation and avoid lipid deposition in other organs. 62
Unfortunately, this expansion has its limits, and eventually adipose tissue becomes dysfunctional 63
(6). 64
Another mechanism that has been postulated to contribute to obesity-related metabolic disorders is 65 defective fatty acid oxidation (FAO). Even though some controversy exists about this topic, mainly 66 due to tissue variability and the obesity state of the subjects, there is evidence of a decrease in FAO 67 capacity in humans and rodents during obesity that contributes to lipid accumulation and 68 lipotoxicity (7-14). Strategies that focus on enhancing FAO have been developed to treat obesity 69 with positive results (15-23). 70
Among obesity-derived adipose tissue dysfunctions, there are two factors that are crucial for the 71 generation of ceramides; key metabolites of sphingolipid (SPL) metabolism that contribute to 72 obesity-related disorders (24, 25). First, the insulin resistance of obese adipose tissue maintains 73 adipocyte lipolysis on. As a result, FFAs are constantly pumped into circulation. One of the main 74 pathways of ceramide synthesis, the de novo pathway, depends on the availability of saturated 75
FFAs (26). Therefore, an increase in saturated FFAs in circulation is a perfect scenario to promote 76 de novo ceramide synthesis. Second, adipocyte cell death and dysfunction due to an excess of 77 nutrients generates local inflammation, which promotes immune cell infiltration in the tissue. 78
Then, inflammation is amplified systemically to reach the rest of the body (6, 27). A second 79 ceramide synthesis pathway, the catabolic conversion of another SPL, sphingomyelin (SM), into 80 ceramide by the action of sphingomyelinases, can be activated by inflammatory signals such as 81
TNFα (28). TNFα is a classical cytokine that is elevated in circulation during obesity and known to 82 cause insulin resistance (29, 30). Thus, both elevated saturated FFAs and inflammation, which are 83 key signatures of obesity, promote ceramide synthesis. 84
Ceramides have been linked to obesity, insulin resistance and metabolic disorders (24, 25). 85
However, most studies have focused on total ceramide levels, rather than the presence of a specific 86 ceramide (31, 32). The lipidomics era has brought the attention to individual ceramide molecular 87 species that are produced via specific pathways and perform distinct functions. Therefore, it is not 88 only a matter of the quantity, but also the quality of ceramide that is modulated in pathological 89
states (33). 90
Two studies have demonstrated an increase in specific ceramide species (palmitoyl ceramide or 91 C16:0 ceramide) in obese humans and mice that inhibits FAO and negatively regulates insulin 92 signaling and energy expenditure (34, 35). These two independent studies provide a link between 93 obesity, insulin resistance and impaired FAO through ceramide action. In this review, we will 94 proteins located in the ER. Interesting recent reviews (41-43) revealed that CerS differ in their: 1) 141 amino acid composition, protein structure and transmembrane topologies, 2) long-chain acyl-CoA 142 specificities and sphingoid base stereospecificity, 3) tissue distribution, 4) transcriptional, post-143 translational and activity regulation, and 5) biological function (Table 1) . These enzymes have 144 emerged as a critical node in phospholipid metabolism. Interestingly, some data suggest that 145 ceramide with a different acyl-chain-length might be associated with cell dysfunction in lipotoxic 146 conditions. C16:0 and C18:0 ceramides are associated with insulin resistance in mice liver (44) and 147 in myotubes from the skeletal muscle of type 2 diabetic patients (45). The identification of putative 148 ceramides at the onset of insulin resistance and in lipotoxicity pushed the research community to 149 carry out many new studies, to discern which CerS is responsible for these events. Recent data 150 obtained from different CerS knockdown showed a high degree of redundancy and inter-regulation 151 between different CerSs (46). Furthermore, knockout mice from CerS1, CerS2, CerS3, CerS4 and 152 CerS5 (47-51) highlight that these enzymes are not only modulators of chain-length in ceramide 153 production, but also control the levels of other bioactive sphingolipids that have different roles 154 depending on the tissue. Data from these studies indicate that CerS5 and CerS6 may be the main 155
CerSs involved in obesity development. New studies are necessary to understand the precise role 156 of each CerS, to discern which ceramide species are toxic in pathological processes such as obesity 157 or insulin resistance, and to develop pharmacological inhibitors of specific CerS to counteract 158 ceramide negative actions. 159 -DES: recently, dihydroceramides have also been considered bioactive lipid species. In obesity 160
there is an imbalance between dihydroceramide/ceramide, and it has been reported that plasma 161 dihydroceramide levels correlate better than ceramides with body mass index (BMI) in cohorts of 162 obese subjects (52, 53). There are two DES1 and 2 enzymes localized in the cytosolic face of ER. prevents Akt phosphorylation. Consequently, the Akt/PKB pathway is blocked, leading to insulin 177 resistance (68-74). In contrast, the insulin-sensitizing hormone adiponectin stimulates ceramidase 178 activity, which enhances ceramide catabolism resulting in increased susceptibility of tissues to 179 insulin, and reduced inflammation and apoptosis (68). 180
Ceramides have also been shown to alter membrane permeability, inhibit electron transport chain 181 (ETC) intermediates, and promote oxidative stress (25, 69). High levels of ceramides are 182 responsible for pancreatic beta-cell apoptosis mediated by reactive oxygen species (ROS) 183 production and mitochondrial dysfunction (70). Both short and long-chain ceramides were shown 184 to increase ROS production in rat heart and liver mitochondria (71-73). Moreover, studies in beta- 
ROLE OF CERAMIDES IN MITOCHONDRIAL FAO AND OBESITY 222
Ceramides are known to promote metabolic disorders, but it was not until recently that two studies 223 identified a specific ceramide, C16:0, as a key negative regulator of insulin sensitivity and FAO in 224 obesity (34, 35). Even though no mechanism of action of C16:0 ceramide was available until now, 225 evidence of its increase during obesity and diabetes can be found in human studies. Increased 226 C16:0 ceramide in human subcutaneous adipose tissue was found and, in female subjects only, it 227 negatively correlated with adiponectin (90). In addition, a subcutaneous and epicardial fat lipid 228 analysis of non-obese, non-diabetic and obese diabetic patients also showed changes in C16:0 229 ceramide. In subcutaneous fat, C16:0 ceramide was higher in obese diabetic subjects than their 230 non-diabetic counterparts, which indicates that C16:0 ceramide increases significantly with the 231 diabetic but not the obese phenotype. In epicardial fat, C16:0 ceramide is significantly higher in 232 both non-diabetic and obese diabetic patients than in non-obese subjects. However, among all lipid 233 changes in these tissues, only C16:0 ceramide in subcutaneous fat positively correlated with 234 HOMA-IR (91). These studies strongly suggest a role of C16:0 in obesity and diabetes. Ceramide action on ETC was previously described (93). However, most of the studies were 268 conducted with short-chain soluble ceramide (71, 73), which is not the most abundant ceramide 269 species in tissues and can exert different actions to the more physiological ceramide species. 270
Nonetheless, some studies focused on the effects of C16:0 ceramide on ETC and demonstrated that 271 C16:0 ceramide inhibits complex IV, which contributes to ROS formation with no effects on 272 mitochondrial membrane potential (72, 92). Oxidative stress is a hallmark of obesity that can 273 inactivate a large number of enzymes. A metabolomics study on HeLa cells revealed that CPT1 is 274 one of the enzymes inhibited by oxidative stress. In this study, they looked at pairs of substrate-275 product altered by H 2 O 2 and other ROS. Among all metabolite changes, the most significant 276 indicated that CPT1 was a major target for oxidative inactivation. Furthermore, CPT1 activity can 277 be recovered by adding catalase to cells. Thus, ROS mediates reversible CPT1 inhibition (94). In 278 summary, this study provides a unique link between oxidative stress and CPT1 inactivation. These 279 are two scenarios present during obesity that can explain decreased FAO. 280
With all this information in mind, we can outline a model in which obesity increases saturated FAs 281 and CerS6, leading to C16:0 accumulation. This can cause ETC dysfunction and generate ROS. 282
The ROS can then inactivate CPT1, decreasing FAO, and as a result promote lipid accumulation 283 within the cells (Fig. 2) . Some human data can be found in the literature supporting this model. A 284 study of endurance training in obese humans showed a decrease in C16:0 ceramide after training, 285 coupled with an increase in CPT1 activity and FAO in muscle, all of which lead to improved 286 glucose tolerance (95). Exercise training decreases C16:0 ceramide and increases CPT1 activity. 287
Overall, it rescues FAO in human obese skeletal muscle and whole body glucose metabolism. 288
Unfortunately, it is widely known that lifestyle interventions fail as a treatment for obesity, since 289 they entails patients' long-term commitment. One strategy that could mimic exercise training is 290 enhancing FAO through CPT1 overexpression. Several animal and cellular models have been 291 developed to increase FAO to treat obesity successfully, and some of them showed lower total 292 ceramide content as part of the improved phenotype (16, 18, 85). However, no specific data on 293 ceramide species were available in most of the studies. Only a few studies showed changes in 294 ceramide species after FAO modulation. In an in vitro study, enhanced FAO in skeletal muscle 295 cells protected them from palmitate-induced lipotoxicity and insulin resistance, which correlated 296 with a decrease in total ceramide and specifically C16:0 ceramide (17). This study supports the 297 idea that enhancing FAO through CPT1 overexpression might be a good strategy to decrease C16:0 298 ceramide and avoid its deleterious effects on metabolism in obese states. Although enhancing FAO 299 is a good strategy to rescue C16:0 ceramide actions during obesity, we are aware that C16:0 300 ceramide has FAO-independent functions in metabolic diseases. Obesity is associated with an 301 increase in endocannabinoid system signaling, which triggers insulin resistance. It has been 302 demonstrated in mice that inhibition of cannabinoid-1 receptor reduces de novo ceramide synthesis 303 through a decrease in expression and activity of SPT, CerS1 and CerS6. This leads to a reduction 304 of C16:0 ceramide, among others. These events protect animals from diet-induced body weight 305 gain, hepatic steatosis, glucose and insulin intolerance (44). This study again implicates C16:0 306 ceramide in metabolic diseases. 307
308

CONCLUDING REMARKS 309
Given the recent findings, research on metabolic diseases should include the role of C16:0 310 ceramide in these pathologies. Obesity increases C16:0 ceramide (34), and circulating levels of 311 C16:0 ceramide might become a metabolic marker of obesity and associated metabolic 312
dysfunctions. An example can be found in human studies with obese subjects who underwent 313 gastric bypasses. After surgery, obese patients had lower body weight and decreased plasma C16:0 314 ceramide levels (96, 97). In addition, a decrease in plasma C16:0 ceramide positively correlates 315 with a reduction in plasma TNFα, an inflammatory cytokine that is involved in insulin resistance 316 (97). In animal models, genetic obese ob/ob mice display increased levels of plasma ceramide. 317 Specifically, C16:0 and C18:0 ceramide are higher than in lean mice (98). Altogether, these data 318 suggest that C16:0 ceramide could be used as a metabolic marker of obesity and associated 319
pathologies. 320
Obesity dysfunctions depend on individual susceptibility. Genetic background differs from 321 individual to individual, predisposing to or protecting from pathologies. C16:0 ceramide could 322 mediate the transition from the obese to the insulin-resistant phenotype, and gene variants of 323 CerS2, CerS5 or CerS6 could have an impact on C16:0 ceramide levels. We could only find one 324 article on CerS gene variants and metabolic diseases. In this study, a human gene variant of CerS2 325 was associated with an increase in albuminuria in patients with diabetes, a common condition that 326 indicates progression of the disease (99). No data were provided on the activity of this CerS2 327 variant or on levels of C16:0 ceramide, but it would be interesting to investigate how many gene 328 variants of CerS2, CerS5 and CerS6 exist in humans, their effects on enzyme activity, and whether 329 they can modulate C16:0 levels and have an impact on metabolic diseases. 330
As it is known that C16:0 ceramide has a negative impact on metabolism it is crucial to develop 331 specific CerS5 and CerS6 inhibitors to treat obesity and associated comorbidities. This is a difficult 332 task, due to the high homology between ceramide synthases. To the best of our knowledge, only 333 one study attempted to develop specific CerS competitive inhibitors derived from the 334 immunosuppressant Fingolimod (FTY720). Compound ST1072 can inhibit CerS4 and CerS6 335 (100), but there are no data yet on in vivo effects under a HFD challenge. Importantly, the new data 336 on regulation of CerS activity by phosphorylation or deacetylation (101, 102) open up new 337 therapeutic options to control C16:0 ceramide production and its negative effects on health. 338
The strategy that we, and other labs, have to treat obesity is to enhance FAO. Enhancing FAO 339 through CPT overexpression forces FFAs to enter into mitochondria for oxidation. Ceramide de 340 novo synthesis relies on saturated FFA availability. In obesity in particular, palmitic acid is 341 essential for C16:0 ceramide formation. By enhancing FAO, it is possible to 1) reduce overall 342 ceramide formation and 2) kidnap the palmitoyl-coA necessary for C16:0 ceramide generation. 343
This could reduce the deleterious effects associated with this obesity-related ceramide species. 344
More studies on enhancing FAO with lipidomic data will be needed to prove this concept. 345
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